home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Anti-Inflammatories: Small Molecule Approaches

 
  April 12, 2012  
     
 
CHI, San Diego, CA
2012-04-17


JAK kinase inhibitors will probably be the first new class of oral anti-inflammatories on the market, with the first one likely to receive approval end of 2012. But which JAK or combinations of JAK enzymes is going to prove the best to inhibit in terms of side effects and overall risk benefit profile to patients? How are the other kinase inhibitors aimed at targeting SYK and BTK, targeted for autoimmune disease but with broader potential in diseases such as cancer, progressing?

 
 
Organized by: Cambridge Healthtech Institute
Invited Speakers: pharmaceutical, clinical, healthcare, and IT professionals
 
Deadline for Abstracts: 2012/04/01
 
Registration: www.drugdiscoverychemistry.com/ifl
E-mail: ndonmez@healthtech.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.